Ongoing Litigation and Voluntary Submissions: Texas Top Cop Shop, Inc. v. Garland and the Corporate Transparency Act
In the ongoing case of Texas Top Cop Shop, Inc., et al. v. Garland, et al., No. 4:24-cv-00478 (E.D. Tex.), the U.S. District Court for the Eastern District of Texas issued a nationwide preliminary injunction on December 3, 2024, halting the enforcement of the...
Important Update: Beneficial Ownership Information Reporting
Recent legal developments have altered the timeline for beneficial ownership information (BOIR) reporting requirements under the Corporate Transparency Act (CTA), including the deadlines for initial filings and extensions granted due to legal challenges. On December...
FDA Declares Zepbound No Longer in Shortage: A Legal Perspective on the Implications for Patients, Pharmacies, and the Industry
On December 19, 2024, the U.S. Food and Drug Administration (FDA) made a critical ruling that has major legal and regulatory consequences for the healthcare sector. The FDA declared that the shortage of tirzepatide, the active ingredient in Eli Lilly’s weight loss...
Breaking News: FDA Reevaluates Tirzepatide Drug Shortage: A Win for the Aesthetics Industry and Compounding Pharmacies
The U.S. District Court for the Northern District of Texas recently released a joint status report in the case Outsourcing Facilities Association v. U.S. Food and Drug Administration (Case No. 4:24-cv-00953-P). This report, filed on November 21, 2024, outlines ongoing...